Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.54 | 0.02 | -0.84 | 0.65 |
| FCF Yield | -4.35% | -17.12% | -17.55% | 5.87% |
| EV / EBITDA | 7.60 | 8.19 | 12.35 | 8.72 |
| Quality | ||||
| ROIC | 4.12% | 3.21% | 0.84% | 4.91% |
| Gross Margin | 36.49% | 35.70% | 34.81% | 42.38% |
| Cash Conversion Ratio | 0.89 | 0.51 | 0.55 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.52% | 11.23% | 10.48% | 14.48% |
| Free Cash Flow Growth | 74.86% | -11.42% | -426.49% | 301.74% |
| Safety | ||||
| Net Debt / EBITDA | 3.86 | 3.99 | 5.97 | 3.77 |
| Interest Coverage | 14.29 | 18.63 | 8.68 | 83.50 |
| Efficiency | ||||
| Inventory Turnover | 1.52 | 1.45 | 1.47 | 1.31 |
| Cash Conversion Cycle | 266.39 | 299.26 | 260.32 | 324.73 |